SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories reports Q3 consolidated net loss at Rs 454.17 crore

30 Oct 2013 Evaluate

Ranbaxy Laboratories has reported results for the third quarter ended September 30, 2013.

The company has reported a net loss Rs 842.23 crore as compared to a net profit of Rs 552.19 crore in the same quarter previous year. Total income of the company has decreased by 3.74% at Rs 1470.18 crore for quarter under review as compared to Rs 1527.36 crore for the quarter ended September 30, 2012.

On the consolidated basis, the group has reported a net loss after taxes, minority Interest and share of proflt/(loss) of associates at Rs 454.17 crore as compared to a net profit of Rs 754.17 crore in the same quarter previous year. However, total income of the group rose 1.93% to Rs 2827.73 crore for quarter under review as against Rs 2774.23 crore in corresponding quarter previous year.

Peers
Company Name CMP
Sun Pharma Inds. 1826.55
Dr. Reddys Lab 1281.00
Cipla 1337.40
Zydus Lifesciences 918.00
Lupin 2370.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×